Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- Submitting institution
-
Imperial College of Science, Technology and Medicine
- Unit of assessment
- 4 - Psychology, Psychiatry and Neuroscience
- Output identifier
- 3264
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(13)61939-X
- Title of journal
- The Lancet
- Article number
- -
- First page
- 1138
- Volume
- 383
- Issue
- 9923
- ISSN
- 0140-6736
- Open access status
- Out of scope for open access requirements
- Month of publication
- January
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
37
- Research group(s)
-
-
- Citation count
- 246
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to the conception and design of the study. The author helped to critique the output for important intellectual content.
- Non-English
- No
- English abstract
- -
